

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Huang 1



| Section 1. Identifying Inform  | nation   |  |
|--|--|--|
| 1. Given Name (First Name)<br>Yu   | 2. Surname (Last Name)<br>Huang                              | 3. Date<br>23-July-2020  |
| 4. Are you the corresponding author?   | Yes ✓ No   | Corresponding Author's Name<br>Weilin Wang   |
| <ul><li>5. Manuscript Title</li><li>Synchronous occurrence of hepatocellu</li><li>with multiple intra-hepatic metastases</li><li>6. Manuscript Identifying Number (if you kn</li><li>HBSN-19-909</li></ul> | ·  | e biliary hamartomas mimicking hepatocellular carcinoma  |
| Section 2. The Work Under Co   | onsideration for Public                                      | ation  |
|  | but not limited to grants, dat                               | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3. Relevant financial  | activities outside the s                                     | ubmitted work.   |
| of compensation) with entities as descri   | ibed in the instructions. Us<br>port relationships that were | ether you have financial relationships (regardless of amount<br>e one line for each entity; add as many lines as you need by<br>e <b>present during the 36 months prior to publication</b> . |
| Section 4. Intellectual Proper   | de Doboute & Com-  |  |
| Intellectual Proper  | rty Patents & Copyrig  | nts  |
| Do you have any patents, whether plan  | ned, pending or issued, bro                                  | oadly relevant to the work? Yes V No   |

Huang 2



| Section 5.   |   |  |  |
|--|---|--|--|
|  | Relationships not covered above   |  |  |
|  | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |  |  |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):  |  |  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest  |  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |   |  |  |
| Section 6.   | Disclosure Statement  |  |  |
| Based on the abo<br>below.   | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |  |
| Dr. Huang has n  | othing to disclose.   |  |  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Huang 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

1

Ye



| Section 1.                                      | Identifying Inform        | ation  |  |  |
|---|---------------------------|--|--|--|
| 1. Given Name (Fir<br>Zhou                      | st Name)                  | 2. Surname (Last Name)<br>Ye                               |  | 3. Date<br>23-July-2020  |
| 4. Are you the corr                             | esponding author?         | Yes ✓ No   | Corresponding Author's Nan<br>Weilin Wang                        | ne   |
| •   |                           | llar carcinoma and multipl                                 | e biliary hamartomas mimic                                       | cking hepatocellular carcinoma   |
| 6. Manuscript Iden<br>HBSN-19-909               | tifying Number (if you kn | ow it)   |  |  |
|   |                           |  | -  |  |
| Section 2.                                      | The Work Under Co         | onsideration for Public                                    | ation  |  |
| any aspect of the su<br>statistical analysis, o | ubmitted work (including  | but not limited to grants, da                              | a third party (government, con<br>ta monitoring board, study des | nmercial, private foundation, etc.) for<br>sign, manuscript preparation,                           |
| Section 3.                                      | Relevant financial        | activities outside the s                                   | ubmitted work.   |  |
| of compensation<br>clicking the "Add            | ) with entities as descri | bed in the instructions. Us<br>port relationships that wer | e one line for each entity; ac                                   | ationships (regardless of amount<br>dd as many lines as you need by<br>onths prior to publication. |
| Section 4                                       |                           |  |  |  |
| Section 4.                                      | Intellectual Proper       | ty Patents & Copyrig                                       | hts  |  |
| Do you have any                                 | patents, whether plans    | ned, pending or issued, bro                                | oadly relevant to the work?                                      | ☐ Yes 🗸 No   |

Ye 2



| Section 5.   |   |  |  |
|--|---|--|--|
| Deculon 5.   | Relationships not covered above   |  |  |
|  | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |  |  |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):  |  |  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest  |  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |   |  |  |
| Section 6.   | Disclosure Statement  |  |  |
| Based on the abo<br>below.   | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |  |
| Dr. Ye has nothii  | ng to disclose.   |  |  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Ye 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Kong 1



| Section 1.                                    | Identifying Inform         | ation  |  |   |
|---|----------------------------|--|--|---|
| 1. Given Name (Fir<br>Yang                    | st Name)                   | 2. Surname (Last Name)<br>Kong                               |  | 3. Date<br>23-July-2020   |
| 4. Are you the corr                           | responding author?         | Yes ✓ No   | Corresponding Author's Nam<br>Weilin Wang                        | ne  |
| •   |                            | ılar carcinoma and multipl                                   | e biliary hamartomas mimic                                       | king hepatocellular carcinoma   |
| 6. Manuscript Ider<br>HBSN-19-909             | ntifying Number (if you kn | ow it)   |  |   |
|   |                            |  |  |   |
| Section 2.                                    | The Work Under Co          | onsideration for Public                                      | ation  |   |
| any aspect of the si<br>statistical analysis, | ubmitted work (including   | but not limited to grants, dat                               | a third party (government, com<br>a monitoring board, study desi | nmercial, private foundation, etc.) for<br>ign, manuscript preparation,                           |
| Section 3.                                    | Relevant financial         | activities outside the s                                     | ubmitted work.   |   |
| of compensation clicking the "Add             | ) with entities as descri  | bed in the instructions. Use<br>port relationships that were | e one line for each entity; ad                                   | tionships (regardless of amount<br>dd as many lines as you need by<br>onths prior to publication. |
| Section 4                                     |                            |  |  |   |
| Section 4.                                    | <b>Intellectual Proper</b> | ty Patents & Copyrig   | hts  |   |
| Do you have any                               | patents, whether planr     | ned, pending or issued, bro                                  | oadly relevant to the work?                                      | ☐ Yes ✓ No  |

Kong 2



| Section 5. Polationships not sovered above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Kong has nothing to disclose.  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Kong 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Zhou 1



| Section 1.                                   | Identifying Inform                                    | nation  |  |
|--|---|---|--|
| 1. Given Name (Fi<br>Dongkai                 | rst Name)   | 2. Surname (Last Name)<br>Zhou  | 3. Date<br>24-July-2020  |
| 4. Are you the cor                           | responding author?                                    | Yes ✓ No  | Corresponding Author's Name<br>Weilin Wang   |
|  |   | ular carcinoma and multip   | e biliary hamartomas mimicking hepatocellular carcinoma  |
| 6. Manuscript Ide<br>HBSN-19-909             | ntifying Number (if you kr                            | now it)   |  |
|  |   |   |  |
| Section 2.                                   | The Work Under Co                                     | onsideration for Public   | ation  |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                              | but not limited to grants, da   | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial                                    | activities outside the s  | ubmitted work.   |
| of compensation clicking the "Add            | the appropriate boxes i<br>n) with entities as descri | in the table to indicate who<br>ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount<br>e one line for each entity; add as many lines as you need by<br>e <b>present during the 36 months prior to publication</b> . |
| Section 4.                                   | Intellectual Proper                                   | rty Patents & Copyrig   | ıhts   |
| Do you have any                              |   |   | oadly relevant to the work? Yes V No   |

Zhou 2



| Section 5. Relationships not covered above  |
|---|
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?   |
| Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest   |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.   |
| Dr. Zhou has nothing to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Zhou 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Ying 1



| Section 1. Iden  | ntifying Information   |                    |   |  |
|--|--|--------------------|---|--|
| 1. Given Name (First Nam<br>Lixiong                                      | ne) 2. Surnar<br>Ying  | me (Last Name)     |   | 3. Date<br>24-July-2020  |
| 4. Are you the correspond  | ding author? Yes   | ✓ No               | Corresponding Author's Nar<br>Weilin Wang | me   |
| 5. Manuscript Title<br>Synchronous occurrence<br>with multiple intra-hep | -  | oma and multiple   | e biliary hamartomas mimi                 | cking hepatocellular carcinoma   |
| 6. Manuscript Identifying HBSN-19-909                                    | Number (if you know it)                                      |                    |   |  |
|  |  |                    |   |  |
| Section 2. The   | Work Under Considerat  | tion for Public    | ation                                     |  |
|  | ed work (including but not lim                               |                    |   | mmercial, private foundation, etc.) for esign, manuscript preparation,                         |
| Section 3. Rele  | vant financial activities                                    | outside the su     | ubmitted work.                            |  |
| of compensation) with  | entities as described in the<br>x. You should report relatio | instructions. Use  | e one line for each entity; a             | ationships (regardless of amount add as many lines as you need by nonths prior to publication. |
| Continue A   |  |                    |   |  |
| Section 4. Intel   | lectual Property Pate  | ents & Copyrig     | hts                                       |  |
| Do you have any paten  | ts, whether planned, pendi                                   | ing or issued, bro | oadly relevant to the work?               | Yes 🗸 No   |

Ying 2



| Section 5.   |   |  |  |  |  |
|--|---|--|--|--|--|
| Section 5.   | Relationships not covered above   |  |  |  |  |
|  | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |  |  |  |  |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):  |  |  |  |  |
| ✓ No other rela  | ✓ No other relationships/conditions/circumstances that present a potential conflict of interest   |  |  |  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |   |  |  |  |  |
| Section 6.   | Disclosure Statement  |  |  |  |  |
| Based on the abo   | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |  |  |  |
| Dr. Ying has not   | hing to disclose.   |  |  |  |  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Ying 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Wang 1



| Section 1.   | Identifying Inform  | ation                       |   |                |  |  |
|--|---|-----------------------------|---|----------------|--|--|
| 1. Given Name (Fi<br>Weilin  |   |                             |   |                |  |  |
| 4. Are you the cor   | rou the corresponding author?                                 |                             |   |                |  |  |
| 5. Manuscript Title Synchronous occurrence of hepatocellular carcinoma and multiple biliary hamartomas mimicking hepatocellular carcinoma with multiple intra-hepatic metastases 6. Manuscript Identifying Number (if you know it) |   |                             |   |                |  |  |
| HBSN-19-909  |   |                             |   |                |  |  |
| Section 2.   | The Work Under Co   | onsiderati                  | on for Publication  |                |  |  |
| any aspect of the s<br>statistical analysis,   | titution <b>at any time</b> recei<br>ubmitted work (including | ve payment of but not limit | or services from a third party (goted to grants, data monitoring b  |                | mmercial, private foundation, etc.) for esign, manuscript preparation,                         |  |
| Section 3.   | Relevant financial  | activities (                | outside the submitted w   | ork.           |  |  |
| of compensation clicking the "Add  | ) with entities as descri                                     | bed in the incort relation  | nstructions. Use one line for<br>nships that were <b>present du</b> | each entity; a | ationships (regardless of amount add as many lines as you need by nonths prior to publication. |  |
| Section 4.   |   |                             |   |                |  |  |
| Section 4.   | Intellectual Proper   | ty Pater                    | nts & Copyrights  |                |  |  |
| Do you have any  | patents, whether plani  | ned, pendin                 | ng or issued, broadly relevant                                      | t to the work? | Yes 🗸 No   |  |

Wang 2



| Section 5. Relationships not covered above   |
|--|
| kelationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Wang has nothing to disclose.  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Wang 3